Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program

• Published in: Future oncology (London, England) England), 2018-11, Vol.14 (26), p.2691-2699
• Main Authors: Maines, Francesca, De Giorgi, Ugo, Procopio, Giuseppe, Facchini, Gaetano, Fratino, Lucia, Sabbatini, Roberto, Gasparro, Donatello, Basso, Umberto, Mosillo, Claudia, Campadelli, Enrico, Massari, Francesco, Sava, Teodoro, Sirotova, Suzana, Messina, Caterina, Scagliarini, Sarah, Conteduca, Vincenza, Verzoni, Elena, Rossetti, Sabrina, Veccia, Antonello, Kinspergher, Stefania, Caffo, Orazio
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Androstenes - pharmacology; Androstenes - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone marrow; Brain cancer; Cancer therapies; Chemotherapy; Clinical outcomes; Clinical trials; Dehydrogenases; Disease; Disease Progression; Docetaxel - pharmacology; Docetaxel - therapeutic use; Drug Resistance, Neoplasm; efficacy; enzalutamide; Hemoglobin; Humans; Italy - epidemiology; Kallikreins - blood; Kaplan-Meier Estimate; Male; Metastasis; Middle Aged; Pain; Patients; Phenylthiohydantoin - analogs & derivatives; Phenylthiohydantoin - pharmacology; Phenylthiohydantoin - therapeutic use; Phosphatase; Progression-Free Survival; Prostate cancer; Prostate-Specific Antigen - blood; Prostatic Neoplasms, Castration-Resistant - blood; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - mortality; Prostatic Neoplasms, Castration-Resistant - pathology; Retrospective Studies; safety
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2018-0113

To collect efficacy and safety data of enzalutamide after docetaxel, we retrospectively evaluated the Italian Named Patient Program results. Two hundred and nine metastatic castration-resistant prostate cancer patients were enrolled. Median age was 73 years. Total 42.1% patients had pain, 14.4% had a performance status of two and 59.8% had a Gleason score ≥8. Total 31.1% had previously received ≥2 chemotherapies, 15.3 and 12% had been previously treated with abiraterone and cabazitaxel, respectively and 14.8% had received both. Median progression-free survival and overall survival were 4.8 and 13.1 months, respectively. A prostate-specific antigen reduction ≥50% was observed in 49.1%. Total 32.7% abiraterone-pretreated patients achieved a biochemical response compared with 56% of abiraterone-naive patients. Enzalutamide was safe and well tolerated. Its antitumor activity in abiraterone-pretreated patients was limited.